An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici

Autores
Langellotti, Cecilia Ana; Gammella, Mariela; Soria, Ivana; Bellusci, Carolina; Quattrocchi, Valeria; Vermeulen, Elba Monica; Mongini, Claudia; Zamorano, Patricia Ines
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Bovine herpesvirus-1 (BoHV-1) uses many mechanisms to elude the immune system; one of them is spreading intracellularly, even in the presence of specific antiviral antibodies. Cytotoxic T lymphocytes (CTLs) are necessary to eliminate the virus. The main preventive strategy is vaccination based on inactivated virus. These vaccines are poor inducers of cellular immune responses, and complicate serological diagnosis and determination of the real prevalence of infection. DNA vaccines are a good option because of the capacity of Differentiating Infected from Vaccinated Animals—(DIVA vaccine)—and may be the best way to induce cytotoxic responses. Although this type of vaccines leads to only weak “in vivo” expression and poor immune responses, incorporation of molecular and/or chemical adjuvants can improve the latter, both in magnitude and in direction. In this study, we have investigated the specific immune responses elicited in mice by DNA vaccines based on the BoHV-1 glycoprotein D (pCIgD) with and without two different adjuvants: a plasmid encoding for murine CD40L (pCD40L) or Montanide™ 1113101PR (101). Mice vaccinated with pCIgD+CD40L, pCIgD+101, and pCIgD+CD40L+101 developed significantly higher specific antibody titers against BoHV-1 than the pCIgD group (p < 0.01). The animals vaccinated with pCgD+pCD40L+101 raised significantly higher levels of IgG2a and IgG2b (p < 0.01 and p < 0.001, respectively) than mice vaccinated with pCIgD alone. On the contrary, when the activity of CTL against cells infected with BoHV-1 was measured, the vaccine pCgD+pCD40L+101 induced significantly higher levels of cytotoxicity activity (p < 0.001) than pCIgD alone. A significant increase in the CD4+ populations in the group receiving pCIgD+CD40L+101 in comparison with the pCIgD group was observed and, also, interferon gamma, interleukin (IL)-6, and IL-17A levels were higher. Considering the results obtained from this study for humoral and cellular responses in mice, the inclusion of pCD40L and 101 as adjuvants in a BoHV-1 DNA vaccine for cattle is highly recommendable.
Instituto de Virología
Fil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gammella, Mariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Gammella, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Soria, Ivana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Bellusci, Carolina. Universidad Nacional de Rio Negro. Sede Atlántica; Argentina
Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vermeulen, Elba Monica. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de células presentadoras de antígeno y respuesta inflamatoria; Argentina
Fil: Mongini, Claudia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Mongini, Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zamorano, Patricia Ines. Universidad del Salvador. Cátedra de Inmunología Aplicada; Argentina
Fuente
Viral Immunology 34 (2) : 68-78 (Marzo 2021)
Materia
Bovine Herpesvirus
Vaccine Adjuvants
Cytotoxicity
Coadyuvantes de Vacunas
Citotoxicidad
Herpes Virus Bovino
Mice Model
Modelo de Ratón
Nivel de accesibilidad
acceso restringido
Condiciones de uso
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/9126
Acceder
id INTADig_7a14c4ec42472a370aeefb8a0860584a
oai_identifier_str oai:localhost:20.500.12123/9126
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in miciLangellotti, Cecilia AnaGammella, MarielaSoria, IvanaBellusci, CarolinaQuattrocchi, ValeriaVermeulen, Elba MonicaMongini, ClaudiaZamorano, Patricia InesBovine HerpesvirusVaccine AdjuvantsCytotoxicityCoadyuvantes de VacunasCitotoxicidadHerpes Virus BovinoMice ModelModelo de RatónBovine herpesvirus-1 (BoHV-1) uses many mechanisms to elude the immune system; one of them is spreading intracellularly, even in the presence of specific antiviral antibodies. Cytotoxic T lymphocytes (CTLs) are necessary to eliminate the virus. The main preventive strategy is vaccination based on inactivated virus. These vaccines are poor inducers of cellular immune responses, and complicate serological diagnosis and determination of the real prevalence of infection. DNA vaccines are a good option because of the capacity of Differentiating Infected from Vaccinated Animals—(DIVA vaccine)—and may be the best way to induce cytotoxic responses. Although this type of vaccines leads to only weak “in vivo” expression and poor immune responses, incorporation of molecular and/or chemical adjuvants can improve the latter, both in magnitude and in direction. In this study, we have investigated the specific immune responses elicited in mice by DNA vaccines based on the BoHV-1 glycoprotein D (pCIgD) with and without two different adjuvants: a plasmid encoding for murine CD40L (pCD40L) or Montanide™ 1113101PR (101). Mice vaccinated with pCIgD+CD40L, pCIgD+101, and pCIgD+CD40L+101 developed significantly higher specific antibody titers against BoHV-1 than the pCIgD group (p < 0.01). The animals vaccinated with pCgD+pCD40L+101 raised significantly higher levels of IgG2a and IgG2b (p < 0.01 and p < 0.001, respectively) than mice vaccinated with pCIgD alone. On the contrary, when the activity of CTL against cells infected with BoHV-1 was measured, the vaccine pCgD+pCD40L+101 induced significantly higher levels of cytotoxicity activity (p < 0.001) than pCIgD alone. A significant increase in the CD4+ populations in the group receiving pCIgD+CD40L+101 in comparison with the pCIgD group was observed and, also, interferon gamma, interleukin (IL)-6, and IL-17A levels were higher. Considering the results obtained from this study for humoral and cellular responses in mice, the inclusion of pCD40L and 101 as adjuvants in a BoHV-1 DNA vaccine for cattle is highly recommendable.Instituto de VirologíaFil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; ArgentinaFil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gammella, Mariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; ArgentinaFil: Gammella, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; ArgentinaFil: Soria, Ivana. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Bellusci, Carolina. Universidad Nacional de Rio Negro. Sede Atlántica; ArgentinaFil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; ArgentinaFil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Vermeulen, Elba Monica. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de células presentadoras de antígeno y respuesta inflamatoria; ArgentinaFil: Mongini, Claudia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; ArgentinaFil: Mongini, Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Zamorano, Patricia Ines. Universidad del Salvador. Cátedra de Inmunología Aplicada; ArgentinaMary Ann Liebert2021-04-19T16:06:15Z2021-04-19T16:06:15Z2021-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/9126https://www.liebertpub.com/doi/10.1089/vim.2020.00821557-8976https://doi.org/10.1089/vim.2020.0082Viral Immunology 34 (2) : 68-78 (Marzo 2021)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repograntAgreement/INTA/PNBIO-1131032/AR./Desarrollo de herramientas biotecnológicas para la prevención y el control de enfermedades pecuarias: vacunas, diagnóstico y eIdemiología molecular.info:eu-repo/semantics/restrictedAccess2025-10-16T09:30:03Zoai:localhost:20.500.12123/9126instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-10-16 09:30:04.122INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
title An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
spellingShingle An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
Langellotti, Cecilia Ana
Bovine Herpesvirus
Vaccine Adjuvants
Cytotoxicity
Coadyuvantes de Vacunas
Citotoxicidad
Herpes Virus Bovino
Mice Model
Modelo de Ratón
title_short An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
title_full An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
title_fullStr An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
title_full_unstemmed An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
title_sort An improved DNA vaccine against bovine herpesvirus-1 using CD40L and a chemical adjuvant induces specific cytotoxicity in mici
dc.creator.none.fl_str_mv Langellotti, Cecilia Ana
Gammella, Mariela
Soria, Ivana
Bellusci, Carolina
Quattrocchi, Valeria
Vermeulen, Elba Monica
Mongini, Claudia
Zamorano, Patricia Ines
author Langellotti, Cecilia Ana
author_facet Langellotti, Cecilia Ana
Gammella, Mariela
Soria, Ivana
Bellusci, Carolina
Quattrocchi, Valeria
Vermeulen, Elba Monica
Mongini, Claudia
Zamorano, Patricia Ines
author_role author
author2 Gammella, Mariela
Soria, Ivana
Bellusci, Carolina
Quattrocchi, Valeria
Vermeulen, Elba Monica
Mongini, Claudia
Zamorano, Patricia Ines
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Bovine Herpesvirus
Vaccine Adjuvants
Cytotoxicity
Coadyuvantes de Vacunas
Citotoxicidad
Herpes Virus Bovino
Mice Model
Modelo de Ratón
topic Bovine Herpesvirus
Vaccine Adjuvants
Cytotoxicity
Coadyuvantes de Vacunas
Citotoxicidad
Herpes Virus Bovino
Mice Model
Modelo de Ratón
dc.description.none.fl_txt_mv Bovine herpesvirus-1 (BoHV-1) uses many mechanisms to elude the immune system; one of them is spreading intracellularly, even in the presence of specific antiviral antibodies. Cytotoxic T lymphocytes (CTLs) are necessary to eliminate the virus. The main preventive strategy is vaccination based on inactivated virus. These vaccines are poor inducers of cellular immune responses, and complicate serological diagnosis and determination of the real prevalence of infection. DNA vaccines are a good option because of the capacity of Differentiating Infected from Vaccinated Animals—(DIVA vaccine)—and may be the best way to induce cytotoxic responses. Although this type of vaccines leads to only weak “in vivo” expression and poor immune responses, incorporation of molecular and/or chemical adjuvants can improve the latter, both in magnitude and in direction. In this study, we have investigated the specific immune responses elicited in mice by DNA vaccines based on the BoHV-1 glycoprotein D (pCIgD) with and without two different adjuvants: a plasmid encoding for murine CD40L (pCD40L) or Montanide™ 1113101PR (101). Mice vaccinated with pCIgD+CD40L, pCIgD+101, and pCIgD+CD40L+101 developed significantly higher specific antibody titers against BoHV-1 than the pCIgD group (p < 0.01). The animals vaccinated with pCgD+pCD40L+101 raised significantly higher levels of IgG2a and IgG2b (p < 0.01 and p < 0.001, respectively) than mice vaccinated with pCIgD alone. On the contrary, when the activity of CTL against cells infected with BoHV-1 was measured, the vaccine pCgD+pCD40L+101 induced significantly higher levels of cytotoxicity activity (p < 0.001) than pCIgD alone. A significant increase in the CD4+ populations in the group receiving pCIgD+CD40L+101 in comparison with the pCIgD group was observed and, also, interferon gamma, interleukin (IL)-6, and IL-17A levels were higher. Considering the results obtained from this study for humoral and cellular responses in mice, the inclusion of pCD40L and 101 as adjuvants in a BoHV-1 DNA vaccine for cattle is highly recommendable.
Instituto de Virología
Fil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gammella, Mariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Gammella, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Soria, Ivana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Bellusci, Carolina. Universidad Nacional de Rio Negro. Sede Atlántica; Argentina
Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Vermeulen, Elba Monica. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental (IMEX). Laboratorio de células presentadoras de antígeno y respuesta inflamatoria; Argentina
Fil: Mongini, Claudia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina
Fil: Mongini, Claudia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zamorano, Patricia Ines. Universidad del Salvador. Cátedra de Inmunología Aplicada; Argentina
description Bovine herpesvirus-1 (BoHV-1) uses many mechanisms to elude the immune system; one of them is spreading intracellularly, even in the presence of specific antiviral antibodies. Cytotoxic T lymphocytes (CTLs) are necessary to eliminate the virus. The main preventive strategy is vaccination based on inactivated virus. These vaccines are poor inducers of cellular immune responses, and complicate serological diagnosis and determination of the real prevalence of infection. DNA vaccines are a good option because of the capacity of Differentiating Infected from Vaccinated Animals—(DIVA vaccine)—and may be the best way to induce cytotoxic responses. Although this type of vaccines leads to only weak “in vivo” expression and poor immune responses, incorporation of molecular and/or chemical adjuvants can improve the latter, both in magnitude and in direction. In this study, we have investigated the specific immune responses elicited in mice by DNA vaccines based on the BoHV-1 glycoprotein D (pCIgD) with and without two different adjuvants: a plasmid encoding for murine CD40L (pCD40L) or Montanide™ 1113101PR (101). Mice vaccinated with pCIgD+CD40L, pCIgD+101, and pCIgD+CD40L+101 developed significantly higher specific antibody titers against BoHV-1 than the pCIgD group (p < 0.01). The animals vaccinated with pCgD+pCD40L+101 raised significantly higher levels of IgG2a and IgG2b (p < 0.01 and p < 0.001, respectively) than mice vaccinated with pCIgD alone. On the contrary, when the activity of CTL against cells infected with BoHV-1 was measured, the vaccine pCgD+pCD40L+101 induced significantly higher levels of cytotoxicity activity (p < 0.001) than pCIgD alone. A significant increase in the CD4+ populations in the group receiving pCIgD+CD40L+101 in comparison with the pCIgD group was observed and, also, interferon gamma, interleukin (IL)-6, and IL-17A levels were higher. Considering the results obtained from this study for humoral and cellular responses in mice, the inclusion of pCD40L and 101 as adjuvants in a BoHV-1 DNA vaccine for cattle is highly recommendable.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-19T16:06:15Z
2021-04-19T16:06:15Z
2021-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/9126
https://www.liebertpub.com/doi/10.1089/vim.2020.0082
1557-8976
https://doi.org/10.1089/vim.2020.0082
url http://hdl.handle.net/20.500.12123/9126
https://www.liebertpub.com/doi/10.1089/vim.2020.0082
https://doi.org/10.1089/vim.2020.0082
identifier_str_mv 1557-8976
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repograntAgreement/INTA/PNBIO-1131032/AR./Desarrollo de herramientas biotecnológicas para la prevención y el control de enfermedades pecuarias: vacunas, diagnóstico y eIdemiología molecular.
dc.rights.none.fl_str_mv info:eu-repo/semantics/restrictedAccess
eu_rights_str_mv restrictedAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Mary Ann Liebert
publisher.none.fl_str_mv Mary Ann Liebert
dc.source.none.fl_str_mv Viral Immunology 34 (2) : 68-78 (Marzo 2021)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1846143533925269504
score 12.712165

Publicaciones similares